Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGFR inhbitors" to "Category:VEGFR inhibitors") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | ||
| − | = | + | ==Diseases for which it is used== |
| + | *[[Esophageal cancer]] | ||
| + | *[[Gastric cancer]] | ||
| − | == | + | ==Also known as== |
| + | *'''Code name:''' YN968D1 | ||
| + | *'''Generic name:''' rivoceranib | ||
| + | *'''Brand name:''' Aitan | ||
| + | |||
| + | ==References== | ||
# Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34(13):1448-54. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/13/1448.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26884585 PubMed] | # Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34(13):1448-54. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/13/1448.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26884585 PubMed] | ||
| Line 19: | Line 26: | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| − | [[Category: | + | [[Category:CFDA approved drugs]] |
Revision as of 03:05, 25 February 2018
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is used
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan
References
- Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016 May 1;34(13):1448-54. Epub 2016 Feb 16. link to original article PubMed